Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results
“2020 was a transformational year for Eton and the momentum has continued through the start of 2021. In recent months, we have seen two of our products commercially launched, completed an important value-creating transaction with our neurology portfolio, and expanded our ALKINDI SPRINKLE franchise to include Canada,” said
Fourth Quarter and Recent Business Milestones
- Launch of ALKINDI® SPRINKLE. Eton launched ALKINDI SPRINKLE late in the fourth quarter of 2020. Initial reception from patients and pediatric endocrinologists has been strong and the company has already seen significant adoption of the product.
- Launch of Alaway® Preservative Free. Eton’s commercial partner, Bausch Health, launched Alaway Preservative Free in all major
U.S. retailers in lateJanuary 2021 . The launch triggered a$1.5 million milestone payment to Eton, and Eton will receive royalties on commercial sales. - Completed the sale of neurology oral liquids portfolio. In
February 2021 , Eton announced the sale of its neurology oral liquids portfolio toAzurity Pharmaceuticals for up to$45 million plus royalties on future sales of the products. - Acquired Canadian Rights to ALKINDI SPRINKLE. In
January 2021 , Eton announced that it acquired Canadian marketing rights to ALKINDI SPRINKLE. The company is actively working to bring the product to Canadian patients as quickly as possible.
ALKINDI SPRINKLE
Eton launched ALKINDI SPRINKLE in late 2020 and promotional activities have accelerated in 2021. The company’s pediatric endocrinology focused sales force has now reached a large number of the company’s initial targets. In addition to virtual meetings, sales reps are beginning to hold in-person meetings with prescribers as COVID restrictions have started to ease. The company expects the rate of in-person meetings to increase in the coming months, which is expected to drive even greater adoption of ALKINDI SPRINKLE. New patient starts have grown every month since launch, and the company expects the growth to continue.
Due to the strong initial reception to ALKINDI SPRINKLE in
Neurology Oral Liquids Transaction
In
Biorphen
Biorphen has experienced steady volume growth as more hospitals have adopted the product, however, the company still expects that overall adoption will be limited until the product is converted from an ampule to a vial container. Eton expects to submit the Prior Approval Supplement needed to enact this container change later this year.
Pipeline Update
| Product | Status |
| ALKDINDI® SPRINKLE | Commercial |
| Alaway Preservative Free® | Commercial |
| Biorphen® | Commercial |
| Dehydrated Alcohol Injection | Filed |
| Zonisamide Oral Susp. | Filed |
| Topiramate Oral Soln. | Filed |
| Lamotrigine for Susp. | Filed |
| Cysteine Injection | Filed |
| Ephedrine RTU Injection | Filed |
| ALKINDI® SPRINKLE - |
TBD |
Dehydrated Alcohol Injection. The product is under review with the FDA, and Eton believes the application remains on track to be approved by its Prescription Drug User Fee Act (“PDUFA”) date of
Zonisamide Oral Suspension. The product is under review with the FDA and has been assigned a PDUFA date of
Topiramate Oral Solution. The product is under review with the FDA and has been assigned a PDUFA date of
Lamotrigine for Oral Suspension. The product’s human factor study is ongoing and expected to be completed shortly. The company expects the results to resubmitted to the FDA shortly, which would allow for an approval in 2021.
Cysteine Injection. The product is under review with the FDA and the company expects to receive tentative approval in 2021. The company’s Paragraph IV litigation against the innovator product, Elcys, is ongoing. The application’s 30-month stay expires in
Ephedrine RTU Injection. The product’s NDA was submitted by Eton’s partner and the review is ongoing with a PDUFA date of
Financial Results
Revenue: Eton reported revenue of
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2020 were
Selling, General, and Administrative (SG&A) Expenses: SG&A expenses for the fourth quarter of 2020 were
Net Loss: Net loss for the fourth quarter of 2020 was
Cash Position: Eton reported cash and cash equivalents of
Conference Call and Webcast Information:
About
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the
Statements of Operations
(in thousands, except per share amounts)
| Three months ended |
For the years ended |
|||||||||||||||
| (Unaudited) | ||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales, net | $ | 81 | $ | 459 | $ | 39 | $ | 459 | ||||||||
| Licensing revenue | — | — | — | 500 | ||||||||||||
| Total net revenues | 81 | 459 | 39 | 959 | ||||||||||||
| Cost of product sales | 300 | 453 | 286 | 453 | ||||||||||||
| Gross (loss) profit | (219 | ) | 6 | (247 | ) | 506 | ||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 3,401 | 233 | 14,104 | 11,555 | ||||||||||||
| General and administrative | 3,800 | 2,429 | 12,760 | 7,552 | ||||||||||||
| Total operating expenses | 7,201 | 2,662 | 26,864 | 19,107 | ||||||||||||
| Loss from operations | (7,420 | ) | (2,656 | ) | (27,111 | ) | (18,601 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest and other income (expense), net | (267 | ) | (40 | ) | (859 | ) | 281 | |||||||||
| Loss before income tax expense | (7,687 | ) | (2,696 | ) | (27,970 | ) | (18,320 | ) | ||||||||
| Income tax expense | — | — | — | — | ||||||||||||
| Net loss | $ | (7,687 | ) | $ | (2,696 | ) | $ | (27,970 | ) | $ | (18,320 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.32 | ) | $ | (0.15 | ) | $ | (1.33 | ) | $ | (1.03 | ) | ||||
| Weighted-average number of common shares outstanding, basic and diluted | 23,809 | 17,924 | 21,010 | 17,761 | ||||||||||||
BALANCE SHEETS
(in thousands, except share and per share amounts)
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 21,295 | $ | 12,066 | ||||
| Accounts receivable, net | 48 | 473 | ||||||
| Inventory | 1,242 | 380 | ||||||
| Prepaid expenses and other current assets | 2,116 | 2,090 | ||||||
| Total current assets | 24,701 | 15,009 | ||||||
| Property and equipment, net | 811 | 1,117 | ||||||
| Intangible assets, net | 575 | 725 | ||||||
| Operating lease right-of-use assets, net | 192 | 160 | ||||||
| Other long-term assets, net | 40 | 61 | ||||||
| Total assets | $ | 26,319 | $ | 17,072 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,344 | $ | 575 | ||||
| PPP loan, current portion | 280 | — | ||||||
| Accrued liabilities | 1,170 | 1,388 | ||||||
| Total current liabilities | 3,794 | 1,963 | ||||||
| Long-term debt, net of discount and including accrued fees | 6,532 | 4,540 | ||||||
| Long-term portion of PPP and EIDL loans | 231 | — | ||||||
| Operating lease liabilities, net of current portion | 99 | 19 | ||||||
| Total liabilities | 10,656 | 6,522 | ||||||
| Stockholders’ equity | ||||||||
| Common stock, |
24 | 18 | ||||||
| Additional paid-in capital | 107,797 | 74,720 | ||||||
| Accumulated deficit | (92,158 | ) | (64,188 | ) | ||||
| Total stockholders’ equity | 15,663 | 10,550 | ||||||
| Total liabilities and stockholders’ equity | $ | 26,319 | $ | 17,072 | ||||
STATEMENTS OF CASH FLOWS
(in thousands)
| For the years ended |
||||||||
| 2020 | 2019 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (27,970 | ) | $ | (18,320 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | 2,576 | 1,888 | ||||||
| Common stock issued for product candidate licensing rights | 1,264 | — | ||||||
| Depreciation and amortization | 651 | 447 | ||||||
| Debt discount amortization | 121 | 16 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 425 | (473 | ) | |||||
| Inventory | (862 | ) | (380 | ) | ||||
| Prepaid expenses and other assets | (20 | ) | (1,361 | ) | ||||
| Accounts payable | 1,769 | (377 | ) | |||||
| Accrued liabilities | (300 | ) | 534 | |||||
| Net cash used in operating activities | (22,346 | ) | (18,026 | ) | ||||
| Cash used in investing activities | ||||||||
| Purchases of property and equipment | (50 | ) | (1,096 | ) | ||||
| Purchase of product licensing rights | — | (750 | ) | |||||
| Net cash used in investing activities | (50 | ) | (1,846 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of long-term debt, net of issuance costs | 1,965 | 4,750 | ||||||
| Proceeds from sales of common stock, net of offering costs | 28,782 | — | ||||||
| Proceeds from PPP and EIDL loans | 511 | — | ||||||
| Proceeds from employee stock purchase plan and stock option exercises | 367 | 453 | ||||||
| Net cash provided by financing activities | 31,625 | 5,203 | ||||||
| Change in cash and cash equivalents | 9,229 | (14,669 | ) | |||||
| Cash and cash equivalents at beginning of year | 12,066 | 26,735 | ||||||
| Cash and cash equivalents at end of year | $ | 21,295 | $ | 12,066 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid for interest | $ | 797 | $ | — | ||||
| Cash paid for income taxes | $ | — | $ | — | ||||
Investor Contact:
dkrempa@etonpharma.com
612-387-3740
Source: Eton Pharmaceuticals